Price (delayed)
$0.2914
Market cap
$12.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
-$21.44M
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator.
There are no recent dividends present for LPTX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.